Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 7/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069619 | 0.91 | RET (0.52) | RETSIGMAR1POLBEGLN1HTR1A | |
| SCHEMBL25502427 | 0.87 | RET (0.50) | RETSIGMAR1EGLN1HTR1ADRD2 | |
| SCHEMBL20148104 | 0.85 | RET (0.48) | RETSIGMAR1POLBHTR1ADRD2 | |
| SCHEMBL20158631 | 0.81 | RET (0.43) | RETPOLBEGLN1 | |
| Trifluoroacetic Acid SCHEMBL20137644 | 0.80 | RET (0.45) | RETSIGMAR1EGLN1HTR1ADRD2 | |
| Trifluoroacetic Acid SCHEMBL29972118 | 0.80 | RET (0.45) | RETSIGMAR1EGLN1HTR1ADRD2 | |
| SCHEMBL25502453 | 0.78 | RET (0.51) | RETSIGMAR1POLBOPRM1 | |
| SCHEMBL25502483 | 0.77 | RET (0.51) | RETSIGMAR1POLBOPRM1 | |
| SCHEMBL20206009 | 0.73 | RET (0.45) | RETEGLN1 | |
| SCHEMBL25502420 | 0.72 | RET (0.51) | RETPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885SIGMAR1 3807/4885POLB 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.